These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 34519163)

  • 1. Chromones: Privileged scaffold in anticancer drug discovery.
    Patil VM; Masand N; Verma S; Masand V
    Chem Biol Drug Des; 2021 Nov; 98(5):943-953. PubMed ID: 34519163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromones bearing amino acid residues: Easily accessible and potent inhibitors of the breast cancer resistance protein ABCG2.
    Roussel E; Moréno A; Altounian N; Philouze C; Pérès B; Thomas A; Renaudet O; Falson P; Boumendjel A
    Eur J Med Chem; 2020 Sep; 202():112503. PubMed ID: 32653696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chromone as a Privileged Scaffold in Drug Discovery: Recent Advances.
    Reis J; Gaspar A; Milhazes N; Borges F
    J Med Chem; 2017 Oct; 60(19):7941-7957. PubMed ID: 28537720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and biological evaluation of chromone-based p38 MAP kinase inhibitors.
    Dyrager C; Möllers LN; Kjäll LK; Alao JP; Dinér P; Wallner FK; Sunnerhagen P; Grøtli M
    J Med Chem; 2011 Oct; 54(20):7427-31. PubMed ID: 21905739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges with chromone as a privileged scaffold in drug discovery.
    Silva CFM; Batista VF; Pinto DCGA; Silva AMS
    Expert Opin Drug Discov; 2018 Sep; 13(9):795-798. PubMed ID: 29985064
    [No Abstract]   [Full Text] [Related]  

  • 6. Chromones as a privileged scaffold in drug discovery: a review.
    Keri RS; Budagumpi S; Pai RK; Balakrishna RG
    Eur J Med Chem; 2014 May; 78():340-74. PubMed ID: 24691058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving the odds of success in antitumoral drug development using scoring approaches towards heterocyclic scaffolds.
    Ion GND; Olaru OT; Nitulescu G; Olaru II; Tsatsakis A; Burykina TI; Spandidos DA; Nitulescu GM
    Oncol Rep; 2020 Aug; 44(2):589-598. PubMed ID: 32627025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and SAR studies of bis-chromenone derivatives for anti-proliferative activity against human cancer cells.
    Venkateswararao E; Sharma VK; Manickam M; Yun J; Jung SH
    Bioorg Med Chem Lett; 2014 Nov; 24(22):5256-9. PubMed ID: 25442319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticancer Activity Study of Chromone and Coumarin Hybrids using Electrical Impedance Spectroscopy.
    Bouhenna MM; Mameri N; Pérez MV; Talhi O; Bachari K; Silva AMS; Luyten W
    Anticancer Agents Med Chem; 2018; 18(6):854-864. PubMed ID: 29380706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computational Approaches Towards Kinases as Attractive Targets for Anticancer Drug Discovery and Development.
    Hameed R; Khan A; Khan S; Perveen S
    Anticancer Agents Med Chem; 2019; 19(5):592-598. PubMed ID: 30306880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An overview of quinoline as a privileged scaffold in cancer drug discovery.
    Musiol R
    Expert Opin Drug Discov; 2017 Jun; 12(6):583-597. PubMed ID: 28399679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quinoline as a privileged scaffold in cancer drug discovery.
    Solomon VR; Lee H
    Curr Med Chem; 2011; 18(10):1488-508. PubMed ID: 21428893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A chromatography-free isolation of rohitukine from leaves of Dysoxylum binectariferum: Evaluation for in vitro cytotoxicity, Cdk inhibition and physicochemical properties.
    Kumar V; Guru SK; Jain SK; Joshi P; Gandhi SG; Bharate SB; Bhushan S; Bharate SS; Vishwakarma RA
    Bioorg Med Chem Lett; 2016 Aug; 26(15):3457-63. PubMed ID: 27363938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chromone, A Privileged Scaffold in Drug Discovery: Developments in the Synthesis and Bioactivity.
    Benny AT; Arikkatt SD; Vazhappilly CG; Kannadasan S; Thomas R; Leelabaiamma MSN; Radhakrishnan EK; Shanmugam P
    Mini Rev Med Chem; 2022; 22(7):1030-1063. PubMed ID: 34819000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coumarins as anticancer agents: a review on synthetic strategies, mechanism of action and SAR studies.
    Thakur A; Singla R; Jaitak V
    Eur J Med Chem; 2015 Aug; 101():476-95. PubMed ID: 26188907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and molecular docking study of new benzofuran and furo[3,2-g]chromone-based cytotoxic agents against breast cancer and p38α MAP kinase inhibitors.
    Amin KM; Syam YM; Anwar MM; Ali HI; Abdel-Ghani TM; Serry AM
    Bioorg Chem; 2018 Feb; 76():487-500. PubMed ID: 29310080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent inhibitors of phosphatidylinositol 3 (PI3) kinase that have antiproliferative activity only when delivered as prodrug forms.
    O'Brien NJ; Amran S; Medan J; Cleary B; Deady LW; Jennings IG; Thompson PE; Abbott BM
    ChemMedChem; 2013 Jun; 8(6):914-8. PubMed ID: 23568455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of chromone-like compounds as potential antileishmanial agents, through the 21
    Silva CFM; Pinto DCGA; Fernandes PA; Silva AMS
    Expert Opin Drug Discov; 2020 Dec; 15(12):1425-1439. PubMed ID: 32783762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative Structure-Cytotoxicity Relationship of 2-(
    Shi H; Nagai J; Sakatsume T; Bandow K; Okudaira N; Sakagami H; Tomomura M; Tomomura A; Uesawa Y; Takao K; Sugita Y
    Anticancer Res; 2018 Jul; 38(7):3897-3906. PubMed ID: 29970510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploiting the Chromone Scaffold for the Development of Inhibitors of Corticosteroid Biosynthesis.
    Gobbi S; Hu Q; Zimmer C; Engel M; Belluti F; Rampa A; Hartmann RW; Bisi A
    J Med Chem; 2016 Mar; 59(6):2468-77. PubMed ID: 26938274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.